A citation-based method for searching scientific literature

Yi-Ching Lee, I-Wen Song, Ya-Ju Pai, Sheng-De Chen, Yuan-Tsong Chen. Sci Rep 2017
Times Cited: 22







List of co-cited articles
214 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.
R Shiang, L M Thompson, Y Z Zhu, D M Church, T J Fielder, M Bocian, S T Winokur, J J Wasmuth. Cell 1994
921
40

Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
F Rousseau, J Bonaventure, L Legeai-Mallet, A Pelet, J M Rozet, P Maroteaux, M Le Merrer, A Munnich. Nature 1994
650
36

Achondroplasia: Development, pathogenesis, and therapy.
David M Ornitz, Laurence Legeai-Mallet. Dev Dyn 2017
83
36

Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Florence Lorget, Nabil Kaci, Jeff Peng, Catherine Benoist-Lasselin, Emilie Mugniery, Todd Oppeneer, Dan J Wendt, Sean M Bell, Sherry Bullens, Stuart Bunting,[...]. Am J Hum Genet 2012
104
31

Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
J S Colvin, B A Bohne, G W Harding, D G McEwen, D M Ornitz. Nat Genet 1996
688
31

Fibroblast growth factor receptor 3 is a negative regulator of bone growth.
C Deng, A Wynshaw-Boris, F Zhou, A Kuo, P Leder. Cell 1996
837
31

A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
Y Wang, M K Spatz, K Kannan, H Hayk, A Avivi, M Gorivodsky, M Pines, A Yayon, P Lonai, D Givol. Proc Natl Acad Sci U S A 1999
167
31


Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
Akihiro Yasoda, Yasato Komatsu, Hideki Chusho, Takashi Miyazawa, Ami Ozasa, Masako Miura, Tatsuya Kurihara, Tomohiro Rogi, Shoji Tanaka, Michio Suda,[...]. Nat Med 2004
265
27

Achondroplasia.
William A Horton, Judith G Hall, Jacqueline T Hecht. Lancet 2007
280
27

Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
Davide Komla-Ebri, Emilie Dambroise, Ina Kramer, Catherine Benoist-Lasselin, Nabil Kaci, Cindy Le Gall, Ludovic Martin, Patricia Busca, Florent Barbault, Diana Graus-Porta,[...]. J Clin Invest 2016
43
27

Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia.
Stéphanie Pannier, Vincent Couloigner, Nadia Messaddeq, Monique Elmaleh-Bergès, Arnold Munnich, Raymond Romand, Laurence Legeai-Mallet. Biochim Biophys Acta 2009
38
27


Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Daniel J Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A O'Neill, Pavel Krejci,[...]. J Pharmacol Exp Ther 2015
57
22

Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Nan Su, Qidi Sun, Can Li, Xiumin Lu, Huabing Qi, Siyu Chen, Jing Yang, Xiaolan Du, Ling Zhao, Qifen He,[...]. Hum Mol Genet 2010
64
22

Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.
L Chen, R Adar, X Yang, E O Monsonego, C Li, P V Hauschka, A Yayon, C X Deng. J Clin Invest 1999
189
22

The Fibroblast Growth Factor signaling pathway.
David M Ornitz, Nobuyuki Itoh. Wiley Interdiscip Rev Dev Biol 2015
896
22

Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.
Cynthia F Bartels, Hulya Bükülmez, Pius Padayatti, David K Rhee, Conny van Ravenswaaij-Arts, Richard M Pauli, Stefan Mundlos, David Chitayat, Ling-Yu Shih, Lihadh I Al-Gazali,[...]. Am J Hum Genet 2004
228
18

Dwarfism and early death in mice lacking C-type natriuretic peptide.
H Chusho, N Tamura, Y Ogawa, A Yasoda, M Suda, T Miyazawa, K Nakamura, K Nakao, T Kurihara, Y Komatsu,[...]. Proc Natl Acad Sci U S A 2001
330
18

Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.
Akihiro Yasoda, Hidetomo Kitamura, Toshihito Fujii, Eri Kondo, Naoaki Murao, Masako Miura, Naotetsu Kanamoto, Yasato Komatsu, Hiroshi Arai, Kazuwa Nakao. Endocrinology 2009
79
18


Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Stéphanie Pannier, Emilie Mugniery, Aurélie Jonquoy, Catherine Benoist-Lasselin, Thierry Odent, Jean-Philippe Jais, Arnold Munnich, Laurence Legeai-Mallet. Bone 2010
20
20

Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Stéphanie Garcia, Béatrice Dirat, Thomas Tognacci, Nathalie Rochet, Xavier Mouska, Stéphanie Bonnafous, Stéphanie Patouraux, Albert Tran, Philippe Gual, Yannick Le Marchand-Brustel,[...]. Sci Transl Med 2013
57
18

FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Federico Di Rocco, Martin Biosse Duplan, Yann Heuzé, Nabil Kaci, Davide Komla-Ebri, Arnold Munnich, Emilie Mugniery, Catherine Benoist-Lasselin, Laurence Legeai-Mallet. Hum Mol Genet 2014
34
18

Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.
Yingli Wang, Ran Xiao, Fan Yang, Baktiar O Karim, Anthony J Iacovelli, Juanliang Cai, Charles P Lerner, Joan T Richtsmeier, Jen M Leszl, Cheryl A Hill,[...]. Development 2005
135
18

Chondrocyte FGFR3 Regulates Bone Mass by Inhibiting Osteogenesis.
Xuan Wen, Xiaogang Li, Yubin Tang, Junzhou Tang, Siru Zhou, Yangli Xie, Jingyuan Guo, Jing Yang, Xiaolan Du, Nan Su,[...]. J Biol Chem 2016
22
18

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Ravi Savarirayan, Melita Irving, Carlos A Bacino, Bret Bostwick, Joel Charrow, Valerie Cormier-Daire, Kim-Hanh Le Quan Sang, Patricia Dickson, Paul Harmatz, John Phillips,[...]. N Engl J Med 2019
58
18

A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type.
Krista A Geister, Michelle L Brinkmeier, Minnie Hsieh, Susan M Faust, I Jill Karolyi, Joseph E Perosky, Kenneth M Kozloff, Marco Conti, Sally A Camper. Hum Mol Genet 2013
41
13

Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene.
Kohji Miura, Ok-Hwa Kim, Hey Ran Lee, Noriyuki Namba, Toshimi Michigami, Won Joon Yoo, In Ho Choi, Keiichi Ozono, Tae-Joon Cho. Am J Med Genet A 2014
47
13

Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells.
Ami Ozasa, Yasato Komatsu, Akihiro Yasoda, Masako Miura, Yoko Sakuma, Yuko Nakatsuru, Hiroshi Arai, Nobuyuki Itoh, Kazuwa Nakao. Bone 2005
46
13


An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene.
Kohji Miura, Noriyuki Namba, Makoto Fujiwara, Yasuhisa Ohata, Hidekazu Ishida, Taichi Kitaoka, Takuo Kubota, Haruhiko Hirai, Chikahisa Higuchi, Noriyuki Tsumaki,[...]. PLoS One 2012
73
13

Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.
Pavel Krejci, Bernard Masri, Vincent Fontaine, Pertchoui B Mekikian, Maryann Weis, Herve Prats, William R Wilcox. J Cell Sci 2005
104
13

Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs.
Naohisa Tamura, Lynda K Doolittle, Robert E Hammer, John M Shelton, James A Richardson, David L Garbers. Proc Natl Acad Sci U S A 2004
202
13

Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B.
Jerid W Robinson, Jeremy R Egbert, Julia Davydova, Hannes Schmidt, Laurinda A Jaffe, Lincoln R Potter. Cell Signal 2017
12
25

Dephosphorylation and inactivation of NPR2 guanylyl cyclase in granulosa cells contributes to the LH-induced decrease in cGMP that causes resumption of meiosis in rat oocytes.
Jeremy R Egbert, Leia C Shuhaibar, Aaron B Edmund, Dusty A Van Helden, Jerid W Robinson, Tracy F Uliasz, Valentina Baena, Andreas Geerts, Frank Wunder, Lincoln R Potter,[...]. Development 2014
61
13

An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
Sabine E Hannema, Hermine A van Duyvenvoorde, Thomas Premsler, Ruey-Bing Yang, Thomas D Mueller, Birgit Gassner, Heike Oberwinkler, Ferdinand Roelfsema, Gijs W E Santen, Timothy Prickett,[...]. J Clin Endocrinol Metab 2013
52
13


Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
Akihiro Yamashita, Miho Morioka, Hiromi Kishi, Takeshi Kimura, Yasuhito Yahara, Minoru Okada, Kaori Fujita, Hideaki Sawai, Shiro Ikegawa, Noriyuki Tsumaki. Nature 2014
129
13

An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
Emilie Mugniery, Romain Dacquin, Caroline Marty, Catherine Benoist-Lasselin, Marie-Christine de Vernejoul, Pierre Jurdic, Arnold Munnich, Valérie Geoffroy, Laurence Legeai-Mallet. Hum Mol Genet 2012
34
13

Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.
Martin Biosse Duplan, Davide Komla-Ebri, Yann Heuzé, Valentin Estibals, Emilie Gaudas, Nabil Kaci, Catherine Benoist-Lasselin, Michel Zerah, Ina Kramer, Michaela Kneissel,[...]. Hum Mol Genet 2016
14
21

Low bone mineral density in achondroplasia and hypochondroplasia.
Masaki Matsushita, Hiroshi Kitoh, Kenichi Mishima, Izumi Kadono, Hiroshi Sugiura, Sachi Hasegawa, Yoshihiro Nishida, Naoki Ishiguro. Pediatr Int 2016
12
25

Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
Yingli Wang, Miao Sun, Victoria L Uhlhorn, Xueyan Zhou, Inga Peter, Neus Martinez-Abadias, Cheryl A Hill, Christopher J Percival, Joan T Richtsmeier, David L Huso,[...]. BMC Dev Biol 2010
59
13

Craniosynostosis.
David Johnson, Andrew O M Wilkie. Eur J Hum Genet 2011
230
13

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.
T Komori, H Yagi, S Nomura, A Yamaguchi, K Sasaki, K Deguchi, Y Shimizu, R T Bronson, Y H Gao, M Inada,[...]. Cell 1997
13


RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
Vivek Shukla, Xavier Coumoul, Rui-Hong Wang, Hyun-Seok Kim, Chu-Xia Deng. Nat Genet 2007
135
13





Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.